AURA — Aura Biosciences Inc
NASDAQ · Healthcare · Biotechnology
$7.43
+$0.00 (+0.00%)
Aura Biosciences Inc (AURA) is a biotechnology company listed on NASDAQ. It is led by Elisabet de los Pinos Ph.D., based in 80 Guest Street, Boston, MA, United States, 02135, with about 106 employees. Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer, as an alternative to bacillus calmette"guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Net income was -$80.6M. AURA currently screens at market cap $406.7M.
Use this AURA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the AURA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the AURA SEC filings page. Lician reads the product cache first so this HTML stays unique to Aura Biosciences Inc even when a live quote feed is slow.
About Aura Biosciences Inc
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer, as an alternative to bacillus calmette"guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
AURA Key Statistics
Market Cap
$406.75M
Volume
557,596
Previous Close
$7.82
Day Range
$7.60 – $7.78
EPS
-$1.75
Revenue
$0.00
Net Income
-$86.92M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
106
AURA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$86.92M | -$76.41M | -$58.76M | -$35.25M |
| EPS (Diluted) | -$1.75 | -$1.93 | -$1.96 | -$8.95 |
Total Assets
$182.50M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$31.69M
Operating Cash Flow
-$79.81M
Free Cash Flow
$0.00
Aura Biosciences Inc Company Information
- Founder, CEO, President & Director
- Elisabet de los Pinos Ph.D.
- Headquarters
- 80 Guest Street, Boston, MA, United States, 02135
- Website
- www.aurabiosciences.com
- Phone
- 617 500 8864
- IPO / Founded
- 2021-10-29
- Sector
- Healthcare
- Industry
- Biotechnology